Researchers have uncovered how key proteins can switch on RAD51, allowing it to repair cancer-causing DNA damage in cells. Women with faulty RAD51 and BRCA1 and BRCA2 genes are at higher risk of developing these cancers.
A recent study by Kelly Klump at Michigan State University reveals that ovarian hormones influence eating disorders in women by turning genetic risk on and off. Changes in hormone levels drive increases in binge eating and emotional eating across the menstrual cycle.
A new study found that longer periods of leisure time sitting were associated with a higher risk of total cancer risk in women, as well as increased risk of multiple myeloma, invasive breast cancer, and ovarian cancer. The association was not observed in men.
Researchers at Johns Hopkins have found that combining fostamatinib with paclitaxel can reduce tumor size in ovarian cancer cells by up to 87 percent. The combination therapy may provide a new treatment option for patients with recurrent advanced ovarian cancer who have developed resistance to standard treatments.
An international genome-wide association study (GWAS) has identified three genetic variants associated with mucinous ovarian carcinomas (MOCs), offering insights into the biology of this disease. The research also highlights the link between MOCs and colorectal cancer, as well as the discovery of a key gene called HOXD9.
Ovarian cancer suppresses immune cells' ability to respond to tumor cells by activating a gene called XBP1. A novel therapy approach aims to restore dendritic cell function and trigger robust immune responses against ovarian tumors.
A new theranostic agent, I-124 PEG-AVP0458, has shown promise in targeting both ovarian and prostate cancer cells for imaging and treatment. The drug compound attaches itself to the targeted tumor sites via positron emission tomography (PET) scanners, enabling personalized cancer therapy.
Researchers discovered ovarian cancer cells can lock into survival mode and avoid chemotherapy destruction. The study, published in Nature, used whole genome sequencing to analyse tumour DNA samples from 91 patients with high-grade serous ovarian cancer.
Researchers at University of California, San Diego, have identified six mRNA isoforms that distinguish ovarian cancer cells from normal cells, offering potential for early diagnosis and targeted therapies. The study's findings may also lead to new therapeutic targets and more effective treatment options.
Researchers at MD Anderson Cancer Center have identified a biomarker that may boost the response to chemotherapy in patients with ovarian cancer. The study found that miR-506 was associated with improved responses to chemotherapy drugs cisplatin and olaparib, leading to better overall survival.
A Cancer Research UK study found that pre-surgery chemotherapy reduces side effects and hospital stays, leading to a better quality of life for patients. The trial challenged the international standard for treating advanced ovarian cancer.
Researchers at NIH solved a mystery about ovarian cell origins and discovered how these cells share information during development. This new understanding may help identify causes of conditions like premature ovarian failure and polycystic ovarian syndrome.
A new screening method can detect twice as many women with ovarian cancer as conventional strategies, according to the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The method uses a statistical calculation to interpret changing CA125 levels in women's blood, providing a more accurate prediction of individual risk.
A new ovarian cancer research team, funded by a $6 million grant, will focus on DNA repair therapies and prevention. The team aims to build on recent clinical advances with PARP inhibitors and develop a new web-based approach to genetic testing and counseling.
Researchers found that patients with anti-TP53 autoantibodies can detect ovarian cancer up to 13 months before rising CA125 levels. The study suggests a novel assay method for earlier detection of the disease.
A study has identified molecular changes that occur in tissue after chemotherapy in ovarian cancer patients. The researchers found that these changes could be potential targets for new, more personalized drugs. The findings have the potential to advance treatments for ovarian cancer.
Researchers at the University of Utah Health have discovered patterns in DNA anomalies that predict a woman's outcome significantly better than tumor stage, also indicating how well she'll respond to platinum therapy. The new method could lead to personalized prognostic and diagnostic laboratory tests.
A recent study suggests that genetic testing for BRCA1 and BRCA2 mutations in women with ovarian cancer can help identify carriers and reduce their risk. The study found that 19% of women with the most common form of ovarian cancer carry these mutations, which is higher than previous estimates.
A study of over 31,000 women with BRCA1 and BRCA2 mutations found that the risk of breast and ovarian cancer varies by mutation type. The findings suggest that knowledge of mutation-specific risks could inform clinical decision-making among carriers.
Researchers found that specific BRCA mutations are linked to higher breast cancer risk and lower ovarian cancer risk, potentially leading to more personalized risk assessment and prevention strategies. The study analyzed data from over 31,000 women with BRCA1 or BRCA2 gene mutations.
A breakthrough discovery by Queen's University researcher Madhuri Koti has identified biomarkers that can predict the success of chemotherapy in ovarian cancer patients. This finding holds promise for improving treatment options and increasing patient survival rates.
Women treated with goserelin during chemotherapy experienced an 8% ovarian failure rate compared to 22% for the control group. Goserelin also improved pregnancy rates by 21% within 5 years post-treatment.
The Anderson Algorithm increases surgical success in advanced ovarian cancer by providing a personalized approach to surgery, resulting in high complete resection rates of over 86%. This milestone is strongly tied to improved survival outcomes for patients.
A Cancer Research UK study found that serous ovarian cancers with diverse genetic profiles are more likely to become resistant to chemotherapy and recur. This variability affects the prognosis of patients with these tumors, leading to earlier deaths compared to those with less varied tumors.
Researchers at The Wistar Institute have identified a new therapeutic target in ovarian clear cell carcinoma, a difficult-to-treat subtype of ovarian cancer. EZH2 inhibition causes regression of ovarian tumors with ARID1A mutation, providing a much-needed therapeutic strategy for clear cell ovarian cancer.
A meta-analysis of 52 studies found that short-term hormone replacement therapy (HRT) use is associated with a significantly increased risk of developing the two most common types of ovarian cancer. Women who used HRT for 5 years or more had a 40% higher likelihood of developing ovarian cancer compared to those who never took HRT.
Researchers at the University of Chicago Medical Center have created a new screening tool for ovarian cancer that can rapidly test compounds to block metastasis. The three-dimensional cell-culture system mimics human tissue and has identified small molecules that inhibit adhesion and invasion.
Researchers discovered a new way to shrink ovarian cancer tumors by inhibiting abnormal angiogenesis. Using a naturally occurring protein inhibitor called 3TSR, the approach improved chemotherapy drug delivery and resulted in significant tumor regression and survival.
A team of UNC genetics researchers discovered how two genes interact to trigger cancer and spur its development. The research found that ARID1A and PIK3CA mutations led to the overproduction of Interleukin-6, a cytokine crucial for cell signaling that triggers inflammation.
Researchers have found that loss of gene PTEN is a common driver event behind high-grade serous ovarian cancer, which is often fatal. Combining image analysis with genetic data helped identify PTEN levels in cancer cells while ignoring normal cells, paving the way for new treatments.
Researchers at MD Anderson Cancer Center discovered that targeting the non-coding microRNA miR569 can increase cell death in ovarian and breast cancers. The study also found that silencing miR569 expression improves survivability outcomes for ovarian patients.
A novel combination therapy using low-dose chemotherapy with an antiangiogenic treatment, 3TSR, improved survival rates in an animal model of ovarian cancer. The treatment resulted in tumor regression, improved blood flow, and more efficient delivery of chemotherapy drugs with reduced side effects.
Scientists have found a biological indicator that can predict which women without BRCA1/2 mutations will respond well to the PARP inhibitor rucaparib. The biomarker is related to genomic loss of heterozygosity, and its presence indicates that patients with ovarian cancers may benefit from treatment.
Researchers found that cirmtuzumab induces senescence in cancer stem cells, degrading their ability to grow and metastasize. Ovarian cancer patients with high levels of ROR1 experienced more aggressive forms of the disease, highlighting the potential of this antibody therapy as a targeted treatment.
Researchers at Ohio State University have discovered a promising therapy combining an oncolytic virus with doxorubicin to treat advanced or recurrent ovarian cancer. The treatment showed significant antitumor activity in animal models, increasing survival and inducing programmed cell death in cancer cells.
Researchers at University of Guelph found a potential breakthrough in treating late-stage ovarian cancer by shrinking tumours and improving drug delivery. This approach may lead to novel treatment options with reduced morbidity and mortality.
Researchers at Lund University discovered that lactose intolerant people are at a reduced risk of developing lung, breast, and ovarian cancers. The study, which analyzed nationwide data from Sweden, suggests that diet plays a crucial role in protecting against these cancers.
Tea and citrus fruits/juices associated with reduced risk of developing ovarian cancer. Flavonols/flavanones found in foods high in these compounds significantly decrease ovarian cancer risk.
A recent study found that a higher overall diet quality was associated with a lower risk of mortality among ovarian cancer survivors. The composite effect of healthy dietary choices on survival suggests that individual components may not be as crucial as previously thought.
The study identifies tiny differences in protein sequences between cancer cells and healthy tissue, enabling the creation of personalized vaccines. The research aims to improve treatment outcomes for patients with ovarian cancer, which often responds well to surgery and chemotherapy but returns lethally within a year or two.
Fertility experts advocate for making ovarian tissue and egg freezing options widely available to healthy women. The techniques have restored fertility in female cancer patients and enabled the birth of nearly 2000 babies without an increase in birth defects.
A study by Myriad Genetics presented at the 2014 European Society for Medical Oncology (ESMO) annual meeting shows that its Tumor BRACAnalysis CDx test identifies cancer-causing BRCA1/2 mutations in 44% more patients than germline blood testing. This could expand treatment options for ovarian cancer patients with these genetic mutations.
A recent study published in PNAS reveals the link between gelsolin protein and ovarian cancer resistance, providing a promising avenue for developing new therapies. By cutting down gelsolin levels, researchers found that chemo-resistant cells become susceptible to chemotherapy.
Research finds HE4 hormone plays key role in modulating ovarian cancer response to hormones and therapies. The study identified a mechanism by which hormonal therapies like Tamoxifen and Fulvestrant restore sensitivity to chemotherapy in HE4-overexpressing tumors.
A phase Ib clinical trial found that olaparib tablets were safe and effective in heavily pretreated ovarian cancer patients, particularly those with BRCA mutations. The treatment regimen provided a response rate of 66 percent and no grade 4 toxicities, making it a promising option for improving cure rates and quality of life.
Ovarian cancer cells use mesothelial cells to spread through the body via fibronectin secretion. The study suggests that mesothelium is an active participant in the spread of ovarian cancer.
Researchers at A*STAR's Institute of Medical Biology have identified a biomarker, Lgr5, to detect ovarian cancer earlier. Bioinformatics analysis has also revealed genes whose mutation status can be used for prognosis and development of personalized treatment.
Researchers at MD Anderson Cancer Center have discovered that circulating tumor cells (CTCs) rely on the HER3 receptor protein to metastasize to the omentum, a fatty tissue covering abdominal organs. High expression of HER3 is associated with shorter survival in ovarian cancer patients.
A study found that oral contraceptive users have significantly lower measures of ovarian reserve compared to non-users, with a marked suppressive effect on anti-Mullerian hormone and antral follicle count. The results suggest that women taking the Pill may need more frequent assessments of their reproductive status.
A 30-year follow-up study found no link between fertility drugs and breast, ovarian, and uterine cancers, except for extended use of clomiphene citrate. The study of 12,193 women treated for infertility showed a higher risk of invasive breast cancer with clomiphene use in 12 or more treatment cycles.
Researchers have discovered a protein called focal adhesion kinase (FAK) that plays a crucial role in ovarian cancer cell growth. A network of signals generated by osteopontin and FAK controls spheroid growth, making it a potential target for new therapies.
Researchers at St. Joseph's Hospital and Medical Center discovered a new treatment for ovarian cancer that improves response rates and prolongs time until cancer recurrence. Trebananib, a peptide-Fc fusion protein, targets angiogenesis by inhibiting angiopoietin 1 and 2 binding to the Tie2 receptor.
Researchers at the University of Adelaide have identified a genetic pathway that suppresses the spread of ovarian cancer. By studying the genetics of platypus and humans, they found that piRNA genes play a crucial role in preventing the growth of cancer cells.
Researchers used gene expression arrays to analyze biopsies from ICON7 patients and found that patients with proliferative and mesenchymal subtypes responded best to bevacizumab. This subtype analysis may help identify patients who will benefit from the treatment, potentially reducing unnecessary toxicity.
A clinical trial has shown that a combination of drugs, including olaparib and cediranib, can significantly improve progression-free survival for patients with recurrent ovarian cancer. The study found that the combination therapy doubled the benefit of using olaparib alone.
A phase I and II clinical trial demonstrated a near doubling of progression-free survival benefit for the combination therapy compared to olaparib alone. The study results showed significant improvement with the use of the combination drug therapy for recurrent ovarian cancer, suggesting a new treatment option for patients.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
A meta-analysis of 44 studies found that breastfeeding, tubal ligation, and oral contraceptives are associated with reduced rates of ovarian cancer in BRCA1 mutation carriers. Smoking may raise the risk of breast cancer for patients with a BRCA2 mutation.
A new study found that ovarian cancer cells become more aggressive and proliferate faster when adhering to soft tissues compared to stiffer environments. The research team used novel techniques to measure cell forces, revealing a three-fold increase in traction forces on soft surfaces for metastatic cells.
A recent study published in the Journal of Community Genetics found that only one in twenty-two high-risk women received BRCA genetic counseling. Despite having a diverse population, no significant differences were associated with factors like age, race, or family size. The researchers urge providers and patients to be more aware of th...